Loading...

Neon Therapeutics

DB:1WQ
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1WQ
DB
$176M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • Neon Therapeutics has significant price volatility in the past 3 months.
1WQ Share Price and Events
7 Day Returns
-1%
DB:1WQ
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-
DB:1WQ
-10.6%
DE Biotechs
-6.2%
DE Market
1WQ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Neon Therapeutics (1WQ) -1% 10.6% 27.1% - - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 1WQ.
  • No trading data on 1WQ.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Neon Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Neon Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €5.198.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Neon Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Neon Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1WQ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.54
NasdaqGS:NTGN Share Price ** NasdaqGS (2019-04-23) in USD $6.21
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Neon Therapeutics.

DB:1WQ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:NTGN Share Price ÷ EPS (both in USD)

= 6.21 ÷ -5.54

-1.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neon Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Neon Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Neon Therapeutics's expected growth come at a high price?
Raw Data
DB:1WQ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Neon Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Neon Therapeutics's assets?
Raw Data
DB:1WQ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.58
NasdaqGS:NTGN Share Price * NasdaqGS (2019-04-23) in USD $6.21
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:1WQ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:NTGN Share Price ÷ Book Value per Share (both in USD)

= 6.21 ÷ 3.58

1.74x

* Primary Listing of Neon Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neon Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Neon Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Neon Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Neon Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Neon Therapeutics expected to grow at an attractive rate?
  • Unable to compare Neon Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Neon Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Neon Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1WQ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1WQ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1WQ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1WQ Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -50 1
2022-12-31 0 -86 1
2021-12-31 0 -75 -83 2
2020-12-31 13 -48 -89 2
2019-12-31 0 -70 -88 3
DB:1WQ Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -63 -83
2018-09-30 -57 -78
2018-06-30 -53 -76
2018-03-31 -47 -66
2017-12-31 -41 -58
2017-09-30 -36 -51
2016-12-31 -24 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Neon Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Neon Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1WQ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Neon Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1WQ Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -1.99 -1.99 -1.99 1.00
2020-12-31 -2.67 -1.61 -4.32 3.00
2019-12-31 -2.85 -1.95 -3.47 4.00
DB:1WQ Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.54
2018-09-30 -9.00
2018-06-30 -35.31
2018-03-31 -35.72
2017-12-31 -34.32
2017-09-30 -33.01
2016-12-31 -30.72

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Neon Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Neon Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Neon Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Neon Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Neon Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Neon Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Neon Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Neon Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Neon Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Neon Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1WQ Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -83.31 18.28 60.43
2018-09-30 -77.55 16.24 53.32
2018-06-30 -75.67 14.24 50.41
2018-03-31 -65.69 12.36 42.94
2017-12-31 -57.93 10.89 37.20
2017-09-30 -50.90 9.88 32.59
2016-12-31 -30.42 7.75 19.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Neon Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Neon Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Neon Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Neon Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Neon Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Neon Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Neon Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Neon Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Neon Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Neon Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Neon Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Neon Therapeutics Company Filings, last reported 3 months ago.

DB:1WQ Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 101.25 0.00 103.31
2018-09-30 122.91 0.00 121.74
2018-06-30 139.25 0.00 138.63
2018-03-31 66.37 0.00 62.09
2017-12-31 81.32 0.00 79.73
2017-09-30 59.09 0.00 56.30
2016-12-31 90.13 0.00 88.49
  • Neon Therapeutics has no debt.
  • Neon Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Neon Therapeutics has sufficient cash runway for 1.6 years based on current free cash flow.
  • Neon Therapeutics has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 41.2% each year.
X
Financial health checks
We assess Neon Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Neon Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Neon Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Neon Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Neon Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Neon Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Neon Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1WQ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1WQ Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Neon Therapeutics has not reported any payouts.
  • Unable to verify if Neon Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Neon Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Neon Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Neon Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Neon Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Neon Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Neon Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Neon Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hugh O’Dowd
COMPENSATION $595,000
AGE 53
TENURE AS CEO 2.6 years
CEO Bio

Mr. Hugh O’Dowd, M.B.A. has been Chief Executive Officer and President of Neon Therapeutics Inc. since September 27, 2016. Mr. O’Dowd joined Neon Therapeutics from Novartis, where he spent more than 20 years in a variety of leadership roles, including Chief Commercial Officer and Head of Global Strategy of Novartis Oncology. In this role, he was responsible for global commercialization for the oncology portfolio, including Global Brand Leadership, Health Economics & Pricing, Early Phase Commercial Development, Strategic Capabilities, Business Development & Licensing and Global Sales Excellence. He has great depth of expertise in oncology, and has played a pivotal role in building Novartis Oncology into one of the world’s leading oncology companies. He has deep experience in pharmaceutical leadership, moving important oncology therapies from clinical development through commercialization. He began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Mr. O’Dowd was Country President and General Manager in the United Kingdom and Ireland. He has been a Director at Neon Therapeutics Inc since October 3, 2016. Mr. O’Dowd holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.

CEO Compensation
  • Insufficient data for Hugh to compare compensation growth.
  • Hugh's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Neon Therapeutics management team in years:

2.4
Average Tenure
57
Average Age
  • The tenure for the Neon Therapeutics management team is about average.
Management Team

Hugh O’Dowd

TITLE
President
COMPENSATION
$595K
AGE
53
TENURE
2.6 yrs

Eric Lander

TITLE
Founder & Director
COMPENSATION
$50K
AGE
61

Yasir Al-Wakeel

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
36
TENURE
1.8 yrs

Richard Gaynor

TITLE
President of Research & Development
COMPENSATION
$473K
AGE
68
TENURE
2.4 yrs

Ed Fritsch

TITLE
Founder & CTO

Jim Allison

TITLE

Nir Hacohen

TITLE

Bob Schreiber

TITLE

Ton Schumacher

TITLE

Cathy Wu

TITLE
Board of Directors Tenure

Average tenure and age of the Neon Therapeutics board of directors in years:

3
Average Tenure
60
Average Age
  • The tenure for the Neon Therapeutics board of directors is about average.
Board of Directors

Cary Pfeffer

TITLE
Chairman of the Board
AGE
56
TENURE
2.6 yrs

Hugh O’Dowd

TITLE
President
COMPENSATION
$595K
AGE
53
TENURE
2.5 yrs

Eric Lander

TITLE
Founder & Director
COMPENSATION
$50K
AGE
61
TENURE
3.5 yrs

Bob Tepper

TITLE
Director
AGE
62
TENURE
5.5 yrs

Steve Sherwin

TITLE
Director
AGE
69
TENURE
3.6 yrs

Meryl Zausner

TITLE
Director
COMPENSATION
$309K
AGE
60
TENURE
1.3 yrs

Bob Kamen

TITLE
Director
AGE
74
TENURE
3.6 yrs

Rob Bazemore

TITLE
Director
AGE
50
TENURE
0.4 yrs

Nina Bhardwaj

TITLE
Member of Scientific Advisor Board

Keith Flaherty

TITLE
Member of Scientific Advisor Board
AGE
47
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Jul 18 Buy Access Industries Holdings Llc Company 29. Jun 18 29. Jun 18 315,000 €13.71 €4,319,784
X
Management checks
We assess Neon Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Neon Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Details
Name: Neon Therapeutics, Inc.
1WQ
Exchange: DB
Founded: 2013
$157,006,755
28,331,344
Website: http://www.neontherapeutics.com
Address: Neon Therapeutics, Inc.
40 Erie Street,
Suite 110,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS NTGN Common Stock Nasdaq Global Select US USD 27. Jun 2018
DB 1WQ Common Stock Deutsche Boerse AG DE EUR 27. Jun 2018
Number of employees
Current staff
Staff numbers
102
Neon Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 22:38
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/03/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.